Altinicline

Altinicline
Clinical data
ATC code	None;
Identifiers
	IUPAC name (2S)-3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine;
CAS Number	179120-92-4 ;
PubChem CID	3036156;
ChemSpider	2300234 ;
UNII	RJ9V9V09VM;
ChEMBL	ChEMBL111659 ;
CompTox Dashboard (EPA)	DTXSID40870143 ;
Chemical and physical data
Formula	C12H14N2
Molar mass	186.258 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c2ncc(C#C)cc2C1CCCN1C;
	InChI InChI=1S/C12H14N2/c1-3-10-7-11(9-13-8-10)12-5-4-6-14(12)2/h1,7-9,12H,4-6H2,2H3/t12-/m0/s1 ; Key:NUPUDYKEEJNZRG-LBPRGKRZSA-N ;
	(verify)

Altinicline (SIB-1508Y, SIB-1765F) is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype.^[1]^[2] It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models,^[3] and progressed as far as Phase II clinical trials for Parkinson's disease,^[4] where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.

References

^ Cosford ND, Bleicher L, Vernier JM, Chavez-Noriega L, Rao TS, Siegel RS, et al. (March 2000). "Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist". Pharmaceutica Acta Helvetiae. 74 (2–3): 125–30. doi:10.1016/S0031-6865(99)00024-2. PMID 10812948.
^ Wagner FF, Comins DL (October 2006). "Expedient five-step synthesis of SIB-1508Y from natural nicotine". The Journal of Organic Chemistry. 71 (22): 8673–5. doi:10.1021/jo0616052. PMID 17064057.
^ Rao TS, Adams PB, Correa LD, Santori EM, Sacaan AI, Reid RT, Cosford ND (October 2008). "Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist". Brain Research. 1234: 16–24. doi:10.1016/j.brainres.2008.07.063. PMID 18692487. S2CID 23547813.
^ The Parkinson Study Group (February 2006). "Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease". Neurology. 66 (3): 408–10. doi:10.1212/01.wnl.0000196466.99381.5c. PMID 16476941. S2CID 31720763.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Cosford ND, Bleicher L, Vernier JM, Chavez-Noriega L, Rao TS, Siegel RS, et al. (March 2000). "Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist". Pharmaceutica Acta Helvetiae. 74 (2–3): 125–30. doi:10.1016/S0031-6865(99)00024-2. PMID 10812948.

[2] Wagner FF, Comins DL (October 2006). "Expedient five-step synthesis of SIB-1508Y from natural nicotine". The Journal of Organic Chemistry. 71 (22): 8673–5. doi:10.1021/jo0616052. PMID 17064057.

[3] Rao TS, Adams PB, Correa LD, Santori EM, Sacaan AI, Reid RT, Cosford ND (October 2008). "Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist". Brain Research. 1234: 16–24. doi:10.1016/j.brainres.2008.07.063. PMID 18692487. S2CID 23547813.

[pmid16476941-4] The Parkinson Study Group (February 2006). "Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease". Neurology. 66 (3): 408–10. doi:10.1212/01.wnl.0000196466.99381.5c. PMID 16476941. S2CID 31720763.

[1]

[2]

[3]

[4]

Clinical data

ATC code	None
Identifiers
IUPAC name (2S)-3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine
CAS Number	179120-92-4^Y
PubChem CID	3036156
ChemSpider	2300234^Y
UNII	RJ9V9V09VM
ChEMBL	ChEMBL111659^Y
CompTox Dashboard (EPA)	DTXSID40870143
Chemical and physical data
Formula	C₁₂H₁₄N₂
Molar mass	186.258 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES c2ncc(C#C)cc2C1CCCN1C
InChI InChI=1S/C12H14N2/c1-3-10-7-11(9-13-8-10)12-5-4-6-14(12)2/h1,7-9,12H,4-6H2,2H3/t12-/m0/s1^Y Key:NUPUDYKEEJNZRG-LBPRGKRZSA-N^Y
(verify)